Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Bladder Cancer treatment details. Biologic therapy. Chemotherapy. Fox Chase Cancer Center, Philadelphia, PA, United States

Survival: 9.7 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: Philadelphia, PA
Hospital: Fox Chase Cancer Center
Journal: Link
Date: 10/2012

This phase 2 study involved pretreated metastatic urothelial cancer patients who were divided into two separate treatment groups. There were 11 patients in group A with a median age of 70 years and 9 were male. Group B had 28 patients with a median age of 69 years and 21 males.

Patients in group A were treated with the biologic therapy agent cetuximab, which is a monoclonal antibody that inhibits the EGFR protein and interferes with cancer cell growth.

Patients in group B were treated with cetuximab and the chemotherapy agent paclitaxel.

The most severe toxicities in group A were of grade 3 and included rash and pruritus (skin toxicity/itching).

There were treatment-related deaths due to unspecified causes in group B. Grade 3-5 rash, fatigue, pain, and infection were reported.

The median overall survival for group A and group B was 3.9 and 9.7 months, respectively.

This study was partially supported by Bristol-Myers Sqibb.

Correspondence: Dr. Yu-Ning Wong; email:

E-mail to a Friend Email Physician More Information